Analyst Price Targets — ATRC
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| February 18, 2026 12:08 pm | — | UBS | $55.00 | $32.97 | TheFly | AtriCure price target lowered to $55 from $60 at UBS |
| February 18, 2026 12:02 pm | William Plovanic | Canaccord Genuity | $53.00 | $32.97 | TheFly | AtriCure price target lowered to $53 from $64 at Canaccord |
| February 18, 2026 11:09 am | — | Oppenheimer | $44.00 | $32.97 | TheFly | AtriCure downgraded to Perform from Outperform at Oppenheimer |
| October 30, 2025 10:27 am | William Plovanic | Canaccord Genuity | $64.00 | $35.44 | StreetInsider | AtriCure Inc. (ATRC) PT Raised to $64 at Canaccord Genuity |
| July 30, 2025 11:07 am | — | BTIG | $54.00 | $35.13 | TheFly | AtriCure price target raised to $54 from $52 at BTIG |
| July 31, 2024 6:57 am | Rick Wise | Stifel Nicolaus | $26.00 | $22.00 | TheFly | AtriCure price target lowered to $26 from $30 at Stifel |
| July 31, 2024 6:51 am | Matt O'Brien | Piper Sandler | $40.00 | $22.00 | TheFly | AtriCure price target lowered to $40 from $65 at Piper Sandler |
| July 31, 2024 4:58 am | Marie Thibault | BTIG | $53.00 | $22.00 | StreetInsider | AtriCure Inc. (ATRC) PT Lowered to $53 at BTIG |
| May 2, 2024 5:54 am | Mike Matson | Needham | $40.00 | $24.76 | StreetInsider | AtriCure Inc. (ATRC) PT Lowered to $40 at Needham |
| May 2, 2024 5:25 am | Marie Thibault | BTIG | $58.00 | $24.76 | StreetInsider | AtriCure Inc. (ATRC) PT Lowered to $58 at BTIG |
Latest News for ATRC
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that it will release its first quarter 2026 financial results on Tuesday, May 5, 2026. AtriCure will host an audio webcast at 4:30 p.m. Eastern Time on Tuesday, May 5, 2026, to…
ArtiCure Chief Science Officer sold 5,000 shares for a transaction value of approximately $149,000 at around $29.83 per share on March 12, 2026. The sale represented 4.91% of Vinayak's direct holdings, reducing direct ownership from 101,875 to 96,875 shares.
Shares of AtriCure, Inc. (NASDAQ: ATRC - Get Free Report) have earned a consensus rating of "Moderate Buy" from the ten analysts that are currently covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and six have given a buy recommendation to the company.
Citigroup Inc. raised its position in AtriCure, Inc. (NASDAQ: ATRC) by 182.0% in the undefined quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 57,085 shares of the medical device company's stock after purchasing an additional 36,839 shares during the period. Citigroup
MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today announced that the company will be participating in the upcoming Citizens Life Sciences Conference. AtriCure's management is scheduled to participate in a fireside chat on Tuesday, March…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for ATRC.
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.